TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7577405

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg for children 6-10 years and 50 mg for children 10-14 years)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Desmopressin (20 micrograms for all age groups)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Amitriptyline/Desmopressin combination
Number of subjects: 45

Group type: COMPARATOR
Intervention: Amitriptyline/Desmopressin
Number of subjects: 45
Study: 2196771

Group type: EXPERIMENTAL
Intervention: Propranolol 180 or 240 mg/day
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study: 6108711

Group type: EXPERIMENTAL
Intervention: PRD‐92 (mast cell stabilizer)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sulfasalazine (control)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PRD‐92
Number of subjects: 43
Study: 31136052

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 641
Study: 28923809

Group type: EXPERIMENTAL
Intervention: Targeted facilitation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Generalized QI facilitation
Number of subjects: 8
Study: 26130352

Group type: EXPERIMENTAL
Intervention: Arthroscopic reduction
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fluoroscopic reduction
Number of subjects: 74
Study: 23447078

Group type: EXPERIMENTAL
Intervention: Test formulation (250 mg acipimox tablet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation (250 mg acipimox tablet)
Number of subjects: 20
Study: 20461438

Group type: EXPERIMENTAL
Intervention: Aprepitant, ondansetron, and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron and dexamethasone (active control)
Number of subjects: 0
Study: 19301086

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg, 1 h prior to incision, re-administered once daily on postoperative days 1-4)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 17261562

Group type: EXPERIMENTAL
Intervention: Ice water immersion (5+/−1 degrees C)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tepid water immersion (24 degrees C)
Number of subjects: 40
Study: 14984373

Group type: EXPERIMENTAL
Intervention: Commercially available herbal preparation STW 5
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Research herbal preparation STW 5‐II
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Bitter candytuft mono‐extract
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 11317478

Group type: EXPERIMENTAL
Intervention: 0.2 mg cerivastatin daily for 7 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 10726721

Group type: EXPERIMENTAL
Intervention: 50 mg losartan/12.5 mg hydrochlorothiazide (L50H12.5C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100 mg losartan monotherapy (L100)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 50 mg losartan
Number of subjects: 24
Study: 8873542

Group type: EXPERIMENTAL
Intervention: 3.75 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 7.5 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 11.25 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 24
Study: 1567188

Group type: EXPERIMENTAL
Intervention: Topical recombinant alpha-2 interferon gel, applied four times daily for four days
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo, applied four times daily for four days
Number of subjects: 387
Study: 3926040

Group type: EXPERIMENTAL
Intervention: Osteopathic physicians palpation of thoracic paravertebral soft tissue (T1-T8)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Excluded group (no intervention specified)
Number of subjects: 62
Study: 29734823

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplement (SQ-LNS) 20 g/d
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Iron and folic acid (IFA) until delivery, then placebo until 6 months postpartum
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Multiple micronutrients (MMNs) until 6 months postpartum
Number of subjects: 1320
Study: 27139495

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI) - one ultrasound guided injection around the affected tendons and advice on tendon care.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Physiotherapist-administered load modification and exercise intervention - education about load modification and a home-based and supervised exercise programme.
Number of subjects: 201

Group type: COMPARATOR
Intervention: Wait and see approach - basic tendon care advice and reassurance in a single session by a trial physiotherapist.
Number of subjects: 201
Study: 24887686

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d for 1 week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/d for 1 week) with meloxicam
Number of subjects: 35
Study: 22635021

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clomiphene Citrate
Number of subjects: 100
Study: 20010420

Group type: EXPERIMENTAL
Intervention: Simulation-based training in hypoxemic events (Group 1)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Simulation-based training in hypotensive events (Group 2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Final testing at Week 6
Number of subjects: 21
Study: 17867950

Group type: EXPERIMENTAL
Intervention: 95% ethanol
Number of subjects: 65

Group type: COMPARATOR
Intervention: 3% STDS
Number of subjects: 65
Study: 16120856

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 microg vaginally)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Vacuum aspiration (standard of care)
Number of subjects: 652
Study: 12133083

Group type: EXPERIMENTAL
Intervention: Nitrous oxide > 40% end tidal concentration
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nitrous oxide < 10% end tidal concentration
Number of subjects: 21
Study: 10093144

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study: 7487212

Group type: EXPERIMENTAL
Intervention: 80 micrograms/kg body weight recombinant human insulin-like growth factor-I (rhlGF-I)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2225606

Group type: EXPERIMENTAL
Intervention: Prostaglandin treatment (self-administered or given at the clinic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-administered prostaglandin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical procedures (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical procedures (general)
Number of subjects: 0
Study: 31030606

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide treatment
Number of subjects: 10948

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10948
Study: 29725878

Group type: EXPERIMENTAL
Intervention: Peer health navigator intervention with electronic personal health record
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care setting (control group)
Number of subjects: 20
Study: 27518661

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 633

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Adalimumab and Placebo
Number of subjects: 633
Study: 25104617

Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance (500 mg/m², day 1) plus best supportive care (BSC)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Pemetrexed maintenance
Number of subjects: 539

Group type: COMPARATOR
Intervention: Pemetrexed maintenance and Placebo
Number of subjects: 539
Study: 22920808

Group type: EXPERIMENTAL
Intervention: Low-partner discrepancy condition
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Moderate-partner discrepancy condition
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: High-partner discrepancy condition
Number of subjects: 135

Group type: COMPARATOR
Intervention: Individual control condition
Number of subjects: 135
Study: 20637958

Group type: EXPERIMENTAL
Intervention: FDC ibuprofen 400 mg/paracetamol 1000 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: FDC ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: All FDC treatments
Number of subjects: 735

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Ibuprofen 100 mg/paracetamol 250 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg/paracetamol 500 mg
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg/paracetamol 1000 mg
Number of subjects: 735
Study: 19463349

Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 1210
Study: 15770240

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 12858958

Group type: EXPERIMENTAL
Intervention: Grasping (one- and two-handed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparative judgment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metric judgment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Grasping (with elevated disks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual estimation (with hands visible)
Number of subjects: 0
Study: 10963021

Group type: EXPERIMENTAL
Intervention: Speech and language therapy (SLT) involvement
Number of subjects: 16
Study: 8886552

Group type: EXPERIMENTAL
Intervention: Radio-opaque markers (ROMs) with a test meal (451 kcal) containing a capsule with 10 ROMs, assessed after 6 hours
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MRI study with 500 ml intralipid 10% (550 kcal)
Number of subjects: 15

Group type: COMPARATOR
Intervention: MRI study
Number of subjects: 15
Study: 1642532

Group type: EXPERIMENTAL
Intervention: Shock group (n=38)
Number of subjects: 132

Group type: COMPARATOR
Intervention: No shock group (n=94)
Number of subjects: 132
Study: 6424492

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 20 mg, thrice daily for 3 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31987407

Group type: EXPERIMENTAL
Intervention: Palbociclib at 125 mg daily, 3 weeks on/1 week off for 2 years with endocrine therapy
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 162
Study: 30014747

Group type: EXPERIMENTAL
Intervention: Subjects with OA risk factors
Number of subjects: 340

Group type: COMPARATOR
Intervention: Subjects without OA risk factors
Number of subjects: 340

Group type: COMPARATOR
Intervention: Comparison of prevalence
Number of subjects: 340
Study: 26471830

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab (both doses)
Number of subjects: 0
Study: 23078587

Group type: EXPERIMENTAL
Intervention: Class 1 compression stockings (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Class 2 compression stockings (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-compliant patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients with a history of multiple episodes of ulceration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Compliant patients
Number of subjects: 100
Study: 21862455

Group type: COMPARATOR
Intervention: Placebo + Regular Sodium Diet (RS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low Sodium Diet (LS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockade (ARB; losartan 100 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ARB + Diuretics (losartan 100 mg/day plus hydrochlorothiazide 25 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: LS and Diuretics
Number of subjects: 33
Study: 19291085

Group type: EXPERIMENTAL
Intervention: Daunorubicin 50 mg/m(2)
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Daunorubicin 35 mg/m(2)
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Cytarabine 200 mg/m(2)
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Cytarabine 400 mg/m(2)
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: PSC‐833 (multidrug resistance modulator)
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Three courses of treatment
Number of subjects: 1273

Group type: EXPERIMENTAL
Intervention: Four courses of treatment
Number of subjects: 1273
Study: 17975181

Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/d (increased to 2 mg/d after 4 weeks if needed)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 274
Study: 15304577

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Cortical lesions
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Increasing age
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Gender and handedness
Number of subjects: 1281
Study: 11843951

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297

Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 9297
Study: 9689829

Group type: EXPERIMENTAL
Intervention: T4 replacement therapy in Group A (Congenital Hypothyroidism)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group B (matched for age, sex, weight, and pubertal stage)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group C (matched for age, sex, weight, and pubertal stage)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long-term T4 replacement therapy
Number of subjects: 12
Study: 8106768

Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg every 24 h i.v. after initial loading every 12 h for three doses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h i.v.)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 46
Study: 2566337

Group type: EXPERIMENTAL
Intervention: 25 mg almitrine bismesylate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 mg almitrine bismesylate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 100 mg almitrine bismesylate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 200 mg almitrine bismesylate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 4443866

Group type: EXPERIMENTAL
Intervention: Rewarming at 38 degrees C skin surface temperature
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rewarming at 35 degrees C skin surface temperature
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rewarming at 36 degrees C skin surface temperature
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rewarming at 37 degrees C skin surface temperature
Number of subjects: 42
Study: 29016549

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 3187

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (ILS)
Number of subjects: 3187

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 3187

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3187
Study: 28802552

Group type: EXPERIMENTAL
Intervention: Pigtail-retained gastrostomy (PG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mushroom-retained gastrostomy (MG)
Number of subjects: 100
Study: 26315143

Group type: EXPERIMENTAL
Intervention: Coping-infused dialogue through patient-preferred live music (CID-PPLM)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 25
Study: 23664987

Group type: EXPERIMENTAL
Intervention: IMVAMUNE (0+7 schedule)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: IMVAMUNE (0+28 schedule)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: IMVAMUNE (0 schedule)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 22028630

Group type: EXPERIMENTAL
Intervention: PCV-7 vaccination in 11 vaccinated villages
Number of subjects: 5441

Group type: COMPARATOR
Intervention: Meningococcal serogroup C conjugate vaccine in 10 control villages
Number of subjects: 5441

Group type: EXPERIMENTAL
Intervention: PCV-7 vaccination
Number of subjects: 5441
Study: 18435772

Group type: COMPARATOR
Intervention: Diet only (D)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 29
Study: 15922233

Group type: EXPERIMENTAL
Intervention: Thoracic spine manipulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 12584834

Group type: EXPERIMENTAL
Intervention: Composite Salvia Injection (CSI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Xueshuantong (Control)
Number of subjects: 68
Study: 10511060

Group type: EXPERIMENTAL
Intervention: Clenoliximab (IDEC‐151), a chimeric monoclonal antibody, administered as a single intravenous infusion.
Number of subjects: 0
Study: 8555987

Group type: EXPERIMENTAL
Intervention: Almitrine 50 mg twice a day by mouth for 60 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Almitrine
Number of subjects: 18
Study: 1785379

Group type: EXPERIMENTAL
Intervention: Neoadjuvant cyclophosphamide + doxorubicin + cisplatin (CAP) plus radiation therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Neoadjuvant methotrexate + vinblastine + doxorubicin + cisplatin (M‐VAC) therapy
Number of subjects: 43
Study: 7059418

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 100 mg daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide plus acebutolol (up to 800 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acebutolol (up to 2000 mg daily)
Number of subjects: 18
Study: 31664428

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass, banding, vertical banded gastroplasty)
Number of subjects: 2007
Study: 28534645

Group type: EXPERIMENTAL
Intervention: Elamipretide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 29386749

Group type: EXPERIMENTAL
Intervention: Telematic cognitive stimulation (TCS)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Mixed TCS/FCS
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 98
Study: 26078713

Group type: EXPERIMENTAL
Intervention: 0.3% gatifloxacin ophthalmic gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.3% gatifloxacin ophthalmic solution
Number of subjects: 150

Group type: COMPARATOR
Intervention: 0.5% levofloxacin ophthalmic solution
Number of subjects: 150
Study: 25057270

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg per day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Betahistine (32 mg per day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761
Number of subjects: 160

Group type: COMPARATOR
Intervention: Betahistine
Number of subjects: 160
Study: 21138337

Group type: EXPERIMENTAL
Intervention: Tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% (TobraDex ST) dosed 1 drop QID for 14 days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Azithromycin ophthalmic solution 1% dosed 1 drop BID for 2 days followed by QD for 12 days
Number of subjects: 122
Study: 22435514

Group type: EXPERIMENTAL
Intervention: Artichoke juice concentrate (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Artichoke juice concentrate (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17570960

Group type: EXPERIMENTAL
Intervention: Group therapy through Internet chat (12-15 weeks, 90 min weekly)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no participation in chat groups)
Number of subjects: 114
Study: 15210929

Group type: EXPERIMENTAL
Intervention: Direct bracket placement
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indirect bracket placement
Number of subjects: 26
Study: 11816130

Group type: EXPERIMENTAL
Intervention: Kreon 25,000 U lipase (A); 3 x 1 caps/day for 2 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kreon 10,000 U lipase (B); 3 x 1 caps/day for 2 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo; 3 x 1 caps/day for 2 weeks
Number of subjects: 60
Study: 9806693

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% with fentanyl 0.001% (10 microg) for wound infiltration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine 0.5% alone (fentanyl 10 microg IM contralaterally)
Number of subjects: 20
Study: 7711339

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg
Number of subjects: 8
Study: 2599722

Group type: EXPERIMENTAL
Intervention: Heavy training load
Number of subjects: 15

Group type: COMPARATOR
Intervention: Light training load
Number of subjects: 15
Study: 17894051

Group type: EXPERIMENTAL
Intervention: L-Tryptophan treatment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no treatment with L-Tryptophan)
Number of subjects: 9
Study: 31733631

Group type: EXPERIMENTAL
Intervention: LSD (0.1 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: d-amphetamine (40 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All substances
Number of subjects: 28